LAWSUITS NEWS & LEGAL INFORMATION
Par Pharmaceutical Companies, Inc PRX Securities Lawsuit
|Company:||Par Pharmaceutical Companies, Inc|
|Class Period:||Aug-2-12 to Aug-16-12|
|Lead Plaintiff Deadline:||Oct-14-12|
|Court:||District of New Jersey|
The complaint charges Par Pharma and its Board and TPG with violations of the 1934 Act. Par Pharma is a U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.
The complaint alleges that defendants failed to disclose material information in a proxy statement filed with the SEC and publicly disseminated in connection with the proposed sale of Par Pharma to TPG. According to the complaint, the proxy statement was materially false and misleading because it made numerous material omissions about the process leading up to the agreement between Par Pharma and TPG and the work performed by Par Pharma' financial advisor, J.P. Morgan Securities LLC, which was retained by Par Pharma to evaluate the fairness of TPG' offer.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
Par Pharmaceutical Companies, Inc PRX Securities Fraud Legal HelpIf you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Par Pharmaceutical Companies, Inc securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.
Published on Aug-16-12
READ MORE Securities Settlements and Legal News